Physician profile
Ashutosh Raina
NPI 1477787794
$12,116.73
in general payments reported to CMS, 2019-2025
36 companies · $2,484 in 2025
The $2,484 reported for 2025 was more than what 81% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,206 · 2020: $772 · 2021: $1,524 · 2022: $1,678 · 2023: $1,722 · 2024: $2,730 · 2025: $2,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,918 · Education: $17.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,917.79 |
| Education | $17.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,707.08 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Tris Pharma INC | $2,332.43 | 2019-2025 | Dyanavel Xr, Quillivant, Onyda Xr |
| Supernus Pharmaceuticals, INC. | $988.64 | 2019-2025 | Qelbree, Qelbree |
| Corium, LLC | $818.60 | 2022-2024 | Azstarys |
| Sk Life Science, INC. | $641.50 | 2022-2025 | Xcopri |
| Jazz Pharmaceuticals INC. | $523.44 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $512.18 | 2019-2022 | |
| Eisai INC. | $479.83 | 2019-2022 | |
| Neurelis, INC. | $452.73 | 2020-2025 | Valtoco |
| Sumitomo Pharma America, INC. | $323.53 | 2023-2024 | Aptiom |
| Collegium Pharmaceutical, INC. | $266.94 | 2025 | Jornay Pm |
| Greenwich Biosciences, INC. | $246.58 | 2019-2021 | |
| Aquestive Therapeutics, INC. | $245.53 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $221.91 | 2019-2024 | Jornay Pm |
| Acadia Pharmaceuticals INC | $212.34 | 2024-2025 | Daybue |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $176.87 | 2019 | |
| Livanova USA, INC. | $136.87 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Takeda Pharmaceuticals U.S.A., INC. | $131.36 | 2020-2021 | |
| Zimmer Biomet Holdings, INC. | $112.81 | 2019 | |
| Zogenix INC. | $79.31 | 2020-2021 | |
| Adlon Therapeutics L.P. | $62.86 | 2021 | |
| Cranial Technologies, INC | $46.86 | 2024-2025 | Doc Band |
| Immedica Pharma US, INC. | $45.59 | 2022-2023 | |
| Biogen, INC. | $44.15 | 2019-2023 | Spinraza |
| Azurity Pharmaceuticals, INC. | $43.61 | 2025 | Zonisade |
| Avadel Cns Pharmaceuticals, LLC | $43.59 | 2025 | Lumryz |
| Ultragenyx Pharmaceutical INC. | $36.31 | 2021 | |
| Alexion Pharmaceuticals, INC. | $33.26 | 2022-2025 | Koselugo |
| Biomarin Pharmaceutical INC. | $29.53 | 2023-2025 | Brineura |
| Teva Pharmaceuticals USA, INC. | $23.80 | 2021 | |
| Itf Therapeutics LLC | $23.46 | 2025 | |
| Noven Therapeutics, LLC | $21.79 | 2024 | Xelstrym |
| Biocodex, INC. | $15.08 | 2021 | |
| Shire North American Group INC | $13.19 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.99 | 2021 | |
| Brainscope Company, INC. | $11.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashutosh Raina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.